Holen Sie sich die Stockscreener-App
3.74
3.31%
0.12
Handel nachbörslich:
3.79
0.05
+1.34%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.62
Offen:
$3.64
24-Stunden-Volumen:
3.95M
Relative Volume:
0.72
Marktkapitalisierung:
$303.34M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.2805
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
+3.89%
1M Leistung:
-9.66%
6M Leistung:
-39.97%
1J Leistung:
-40.73%
1-Tages-Spanne:
$3.55
$3.9072
1-Wochen-Bereich:
$3.335
$3.9072
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.74 | 274.14M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Transcript : Altimmune, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Shareholders - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results - Benzinga
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Altimmune Faces Investor Lawsuit Over Disappointing Pemvidutide Trial – What Investors Need to Know - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - FinancialContent
Berger Montague PC Announces Class Action Filed Against Altimmune, Inc. (ALT) for Alleged Securities Violations - TradingView
Altimmune (ALT) Sees Adjusted Price Target by B. Riley Securitie - GuruFocus
UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating - MarketScreener
Altimmune, Inc. (NASDAQ:ALT) Q2 2025 Earnings Call Transcript - Insider Monkey
B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating - MarketScreener
Altimmune 2025 Q2 Earnings Improved Net Loss - AInvest
Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... - Yahoo Finance
Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cas - GuruFocus
Undervalued Innovators in Biotech: Assessing Altimmune and INmune Bio's High-Risk, High-Reward Potential - AInvest
Altimmune Reports Promising Trial Results and Financial Growth - TipRanks
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. - GlobeNewswire
Altimmune stock rises on promising Q2 report (ALT) - Seeking Alpha
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Morningstar
What makes Altimmune Inc. stock price move sharplyHighest Potential Swing Stocks - thegnnews.com
Altimmune, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Altimmune Q2 2025 beats EPS forecast, stock rises - Investing.com
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
Altimmune Announces Second Quarter 2025 Financial Results and Business Update - Yahoo Finance
Altimmune, Inc. Sued for Securities Law Violations – - GlobeNewswire
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
What moving averages say about Altimmune Inc.Weekly Growth Portfolio Performance Summary - Newser
Published on: 2025-08-11 21:36:11 - Newser
Altimmune, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & ... - Bluefield Daily Telegraph
Altimmune, Inc. (ALT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Altimmune Board Appoints Jerry Durso as Chairman - citybiz
Shareholders of Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your RightsALT - Barchart.com
Altimmune Appoints Jerry Durso as Chairman as Company Advances to Phase 3 Development of Pemvidutide - Quiver Quantitative
Altimmune appoints Jerry Durso as board chairman - Investing.com
Strategic Shift: Altimmune Taps Commercial Expert Jerry Durso as Chairman Before Crucial MASH Drug Phase 3 - Stock Titan
Analyzing recovery setups for Altimmune Inc. investorsShort-Term Sector Movement Forecast Generator - Newser
Heatmap analysis for Altimmune Inc. and competitorsWealth Accumulation Outlook for Safe Investors - Newser
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
Can Altimmune Inc. recover in the next quarterWeekly Chart Watchlist with Trade Guidance - Newser
Altimmune (ALT) to Release Quarterly Earnings on Tuesday - Defense World
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Eastern Progress
Securities Fraud Class Action Filed Against Altimmune, Inc. (ALT)Levi & Korsinsky Reminds Investors of October 6, 2025 - ACCESS Newswire
Volatility clustering patterns for Altimmune Inc.Free Scalable Portfolio Growth Suggestions - Newser
Predicting Altimmune Inc. trend using moving averagesMachine Learning Intraday Signal Forecast - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
Altimmune's Securities Fraud Litigation: A Cautionary Tale for Biotech Investors - AInvest
Faruqi & Faruqi investigates Altimmune securities class action lawsuit. - AInvest
ALT Investors Have the Opportunity to Lead the Altimmune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):